CPHI Frankfurt 2025 is set to become a significant event for the global biopharmaceutical sector, emphasizing advancements in manufacturing, digital transformation, and collaboration across the industry. Scheduled for October 28–30, 2025, at Messe Frankfurt, this gathering will bring together over 260 experts from regulatory agencies, biotech startups, manufacturing companies, and supply chain leaders.
The agenda will cover pressing topics in drug development, including the integration of artificial intelligence (AI), digital transformation, and sustainability—critical areas influencing how biopharmaceutical technologies are created, scaled, and delivered worldwide.
“The 2025 event showcases the scale of innovation within the pharmaceutical field as well as the necessity for connected leadership and diverse perspectives,” stated Tara Dougal, event director for Informa Markets, in a press release. “Our lineup of speakers provides a mix of experience and forward-thinking, addressing the primary challenges and opportunities facing the pharmaceutical industry today.”
The newly introduced Leadership Summit, sponsored by Ensera (previously known as SteriPack), will serve as a pivotal platform for discussion among executives. It will focus on crucial issues such as pharmaceutical resilience, mergers and acquisitions, access to medicines, and the effects of geopolitical changes on global supply chains. The summit aims to highlight long-term strategies and align policies to bridge the gap between regulatory objectives and the practicalities of drug production.
The conference will host seven specialized tracks aimed at exploring essential aspects of pharmaceutical manufacturing and development:
- Packaging and Device Innovation (Hall 8.0): Focused on patient-centric packaging, connected devices, and regulatory strategies for combination products.
- Future of Pharma and Ingredients (Hall 8.0): Discussions on advancements in API design, digital chemistry, and the modernization of regulatory pathways.
- Next-Gen Bio (Hall 4.1): Addressing challenges in scaling biologics, cell and gene therapies, and messenger RNA platforms.
- Clinical Innovation (Hall 6.1): Exploring the use of AI, digital endpoints, and decentralized trial models to enhance patient recruitment and data integrity.
- Manufacturing 5.0 (Hall 4.1): Insights into smart factories, machine learning integration, and operational excellence in production.
- Sustainable Futures (Hall 4.0): Strategies for low-emission manufacturing, circular pharma, and responsible sourcing.
- Spotlight Stage (Hall 4.0): Updates on cleanroom technologies and sustainability in production.
Informa Markets states that each track was developed in partnership with global organizations, such as IQVIA, Medicines for Europe, CEPI, Environmental Financial Consulting Group, and PSCI. This collaboration ensures the content remains aligned with the latest insights and priorities within the industry.
The event will feature a diverse array of speakers, including experts from government, academia, and multinational biopharmaceutical companies, reinforcing CPHI Frankfurt as a vital forum for the advancement of biopharmaceutical technology. Through a combination of technical sessions and leadership discussions, the conference seeks to influence the ongoing conversation about efficiency, sustainability, and digitalization throughout the entire drug development lifecycle.
